ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2025
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • 2020-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 0633

Diffuse Alveolar Hemorrhage in ANCA-Associated Vasculitis (AAV) and Systemic Lupus Erythematosus (SLE): A Comparative Analysis

Sai Shanmukha Sreeram Pannala1, Medha Rajamanuri2, Srikar Sama3, Fares Saliba4, Omar Mourad5, Elizabeth Fagin6, Koushik Varma Sangaraju7, Veena Katikineni8 and Anastasia Slobodnick9, 1Northwell health/Staten Island university Hospital, new york city, NY, 2Southern Illinois University School of Medicine, Springfield, IL, 3University of California San Francisco Fresno, Fresno, CA, 4Staten Island University Hospital, Staten Island, NY, 5Zucker School of Medicine at Hofstra/Northwell at Staten Island University Hospital, Staten Island, NY, 6Staten Island University Hospital, Teaneck, NJ, 7St. Luke's University Health Network, Bethlehem, PA, 8Desert Orthopaedic and Rheumatologic Institute, Apple Valley, CA, 9Northwell, Staten Island, NY

Meeting: ACR Convergence 2025

Keywords: ANCA associated vasculitis, Mortality, risk factors, socioeconomic factors, Systemic lupus erythematosus (SLE)

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Sunday, October 26, 2025

Title: (0593–0640) Systemic Lupus Erythematosus – Diagnosis, Manifestations, & Outcomes Poster I

Session Type: Poster Session A

Session Time: 10:30AM-12:30PM

Background/Purpose: Diffuse alveolar hemorrhage (DAH) is a rare but severe complication in Systemic Lupus Erythematosus (SLE), occurring in up to one-third of cases at disease onset. In ANCA-associated vasculitis (AAV), the prevalence of DAH is around 25%, with high morbidity and mortality. DAH in both SLE and AAV requires prompt investigation, presenting challenges in initiating life-saving treatments. The objective of this study is to compare the in-hospital mortality in patients with DAH secondary to AAV versus DAH secondary to SLE, aiming to inform management strategies and improve clinical decision-making.

Methods: We used the National Inpatient Sample database from Jan 2020 to Dec 2022 to compare baseline characteristics and outcomes of patients with DAH due to AAV versus SLE. Both groups were analyzed for demographic factors, comorbidities, hospital-related variables, and clinical outcomes. Key outcomes included length of stay (LOS), total charges, and in-hospital mortality, with logistic regression used to assess factors associated with mortality.

Results: A total of 1,470 patients with AAV + DAH and 915 patients with SLE + DAH were identified. In the AAV + DAH group, 54.2% were female, compared to 50% in the SLE + DAH group. The mean age for AAV + DAH patients was significantly higher at 55.34 years, compared to 43.25 years in the SLE + DAH group. Racial distribution showed 63.4% of AAV + DAH patients were White, compared to 62.5% in the SLE + DAH group. AAV + DAH patients had a higher proportion of severe comorbidities (38.8%) compared to SLE + DAH (37.5%). Hospital region distribution showed SLE + DAH patients were more likely to be admitted to hospitals in the South (50%) compared to AAV + DAH (27.3%). More SLE + DAH patients were admitted to large hospitals (87.5%) compared to AAV + DAH (60.1%) (Fig 1). The mean LOS was 16.30 days for AAV + DAH and 15.87 days for SLE + DAH, with total charges for AAV + DAH higher at $273,083 compared to $233,180 for SLE + DAH. The mortality rate for AAV + DAH was 16.4%, compared to 12.5% for SLE + DAH (p = 0.7671). Logistic regression showed no significant difference in mortality between the two groups. (OR 0.73, p = 0.7680).

Conclusion: This study highlights the similarities and differences in the clinical characteristics, comorbidities, and healthcare burden of DAH secondary to AAV versus SLE. While both groups share significant morbidity and mortality, AAV + DAH patients were older, had more severe comorbidities, and incurred higher healthcare costs compared to SLE + DAH patients. Despite these differences, there was no significant difference in in-hospital mortality between the two groups, suggesting that the severity of DAH may not differ substantially based on the underlying disease. The findings underscore the need for further research to better understand the impact of DAH in these distinct patient populations.

Supporting image 1Figure 1: Baseline comparison of Diffuse Alveolar Hemorrhage (DAH) due to Systemic Lupus Erythematosus (SLE) versus ANCA-associated vasculitis (AAV).


Disclosures: S. Pannala: None; M. Rajamanuri: None; S. Sama: None; F. Saliba: None; O. Mourad: None; E. Fagin: None; K. Sangaraju: None; V. Katikineni: None; A. Slobodnick: None.

To cite this abstract in AMA style:

Pannala S, Rajamanuri M, Sama S, Saliba F, Mourad O, Fagin E, Sangaraju K, Katikineni V, Slobodnick A. Diffuse Alveolar Hemorrhage in ANCA-Associated Vasculitis (AAV) and Systemic Lupus Erythematosus (SLE): A Comparative Analysis [abstract]. Arthritis Rheumatol. 2025; 77 (suppl 9). https://acrabstracts.org/abstract/diffuse-alveolar-hemorrhage-in-anca-associated-vasculitis-aav-and-systemic-lupus-erythematosus-sle-a-comparative-analysis/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2025

ACR Meeting Abstracts - https://acrabstracts.org/abstract/diffuse-alveolar-hemorrhage-in-anca-associated-vasculitis-aav-and-systemic-lupus-erythematosus-sle-a-comparative-analysis/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

Embargo Policy

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology